Specifically, we found that treatment with the IDH2 inhibitor AG221 showed efficacy in Jak2/Idh2-mutant MPN, including attenuation of myeloid expansion, reversal of stem cell expansion, and a reduction in the mutant allele burden. Here, IDH2 is linked to myeloproliferative disorder.